Good News Today — Nature Cash, Lagoon Revival & a Rare Childhood Disease Breakthrough
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Good News Today — Nature Cash, Lagoon Revival & a Rare Childhood Disease Breakthrough
-
Lu par :
-
De :
(00:01:10) California Lagoon Moves From Planning to Progress
(00:02:32) A Rare Childhood Disease Gets Closer to a Treatment
(00:03:25) Closing
Today's episode covers three stories that share a common thread: doors that were previously closed are opening.
First, the Big Nature Impact Fund has secured thirty-five million pounds in private backing from insurers and philanthropies — a landmark moment for conservation finance. By aggregating smaller woodland, peatland, and habitat projects into a single managed fund, Finance Earth has created a structure that institutional investors can finally work with. The fund is targeting ninety to one hundred and twenty million pounds within eighteen months. It's early, but the financial model for conservation at scale is becoming real.
Second, Buena Vista Lagoon in California — the state's very first ecological reserve, designated in 1968 — has received a one million dollar federal grant to move from planning into active design and permitting. What makes the Audubon Society's restoration project notable isn't just that it's finally moving: the design deliberately builds in wetland migration space, allowing the habitat to shift inland as sea levels rise over coming decades. Long-range climate thinking, baked in from the start.
Third, Beren Therapeutics has presented promising clinical data for adrabetadex, a drug targeting infantile-onset Niemann-Pick disease type C — a rare and severe neurological condition affecting young children. The data shows the drug can slow disease progression when given early. An FDA decision is being targeted for November 2026. Nothing is guaranteed, but for a disease that long had almost no answers, a genuine clinical signal is significant.
Three stories. Private capital moving into nature. A stalled restoration finally accelerating. A rare childhood disease with a real treatment candidate on the horizon. This is Good News Today.
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment